The China Center for Drug Evaluation (CCDE) is an organization responsible for the evaluation and regulation of drugs in China. It plays a crucial role in ensuring the safety and efficacy of pharmaceutical products through the acceptance and technical review of applications for drug clinical trials. The CCDE recently issued updated guidelines on safety information assessment and drug real-world study design, demonstrating its commitment to staying at the forefront of drug evaluation practices. With its approval of Phase II clinical trials for Transcenta, a leading biopharmaceutical company, the CCDE continues to support the advancement of innovative therapies in China.

Expert Commentary | China Updates Clinical Trial Guidance on “Safety Information Assessment and ... On July 10, 2023, China's Center for Drug Evaluation.

China's Center for Drug Evaluation has issued Drug Real-World Study Design & Protocol Framework Draft Guidelines for industry stakeholder comments until ...

Transcenta announces that it has received approval from China Center for Drug Evaluation (CDE) to initiate Phase II clinical trial of ...

China Center for Drug Evaluation

Find contacts at this company